Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2016

  • ID: 3753877
  • Drug Pipelines
  • 39 pages
  • Global Markets Direct
1 of 5
Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2016

Summary

‘Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Review, H1 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted pipeline therapeutics.

The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) Overview

Therapeutics Development

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Stage of Development

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Therapy Area

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Indication

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Pipeline Products Glance

Early Stage Products

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Companies

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Products under Development by Universities/Institutes

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Companies Involved in Therapeutics Development

Apogenix GmbH

BioInvent International AB

Pfizer Inc.

Pieris Pharmaceuticals, Inc.

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Drug Profiles

Aptamer to Antagonize CD137 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize 41BB for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-342 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-343 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize CD137 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ultra-41BBL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

utomilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Dormant Projects

Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) - Featured News & Press Releases

Mar 17, 2016: Pieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data for Its Lead Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2016 Annual Meeting of the American Association for Cancer Research (AACR)

Nov 06, 2015: Pieris Pharmaceuticals Presents Data at SITC Conference on Lead Immuno-Oncology Program Demonstrating Selective Tumor-Targeted Immune Responses

Sep 21, 2015: Pieris Pharmaceuticals Presents Positive Preclinical Data on Lead Bispecific Immuno-Oncology Program

May 13, 2015: MorphoSys To Present Data On PF-05082566 at American Society of Clinical Oncology Annual Meeting

Dec 22, 2014: MorphoSys Announces Clinical Milestone in Oncology Program

Dec 22, 2003: MorphoSys Forges Therapeutic Antibody Collaboration With Pfizer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Apogenix GmbH, H1 2016

Pipeline by BioInvent International AB, H1 2016

Pipeline by Pfizer Inc., H1 2016

Pipeline by Pieris Pharmaceuticals, Inc., H1 2016

Dormant Projects, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Apogenix GmbH
BioInvent International AB
Pfizer Inc.
Pieris Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll